Forest acquires glucokinase portfolio for up to $1.1 billion
This article was originally published in Scrip
Executive Summary
Forest Laboratories is to pay $50 million upfront and up to $1.055 billion in milestones for the development and commercialisation rights to the private US company TransTech Pharma's portfolio of liver-selective small-molecule glucokinase activators (GKAs).